Affiliation:
1. Department of Cardiology, Department of Medicine I LMU University Hospital, LMU Munich Munich Germany
2. German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance Munich Germany
3. Cardiovascular Research Foundation New York NY USA
4. St. Francis Hospital and Heart Center Roslyn NY USA
5. Saint Luke’s Mid America Heart Institute and University of Missouri‐Kansas City Kansas City MO USA
Abstract
Background
Right‐sided heart failure (HF) due to severe tricuspid regurgitation (TR) is associated with reduced quality of life (QoL). Here, we analyzed the impact of TR on specific QoL dimensions and the effect of transcatheter tricuspid valve intervention (TTVI) on individual QoL items.
Methods and Results
In this study, we included 174 patients with HF (49% women; median age, 79 years; 97% New York Heart Association ≥3) with baseline QoL assessment undergoing TTVI by transcatheter edge‐to‐edge‐repair at our center between April 2016 and March 2022. QoL was assessed by the standardized Minnesota Living With HF Questionnaire. QoL change after TTVI and correlation to functional end points were analyzed. In addition, all QoL domains and the 21 individual items of the Minnesota Living With HF Questionnaire were analyzed. TTVI significantly reduced TR (TR ≥3: baseline 95%, 1‐year‐follow‐up 7%;
P
<0.001). Total Minnesota Living with HF Questionnaire score improved from 37 (interquartile range, 26–50) points to 31 (interquartile range, 17–42) points (median follow‐up‐interval, 355 days;
P
<0.001). QoL improvement was associated with positive New York Heart Association class, 6‐minute walking distance, and actigraphy changes (all
P
<0.05). The detailed analysis revealed that all items of the physical‐related QoL dimension were impaired at baseline and strongly improved after TTVI. In contrast, the emotional and “social” Minnesota Living With HF Questionnaire dimensions were largely unaffected at baseline, yet specific items improved with TTVI.
Conclusions
In this single‐center study, we delineate the QoL‐associated disease burden of TR and identify specific QoL items that improved after TTVI. Our findings support TTVI in patients with reduced QoL and may add to the development of specific tools assessing the functional status of an increasing patient population undergoing TTVI.
Publisher
Ovid Technologies (Wolters Kluwer Health)